PharmStar Pharmaceuticals Names Dr. Antonio Hernandez to Medical Advisory Board
August 10 2011 - 9:30AM
Marketwired
PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company")
announced today that Dr. Antonio Hernandez has accepted an
invitation to join the Company's Medical Advisory Board (MAB).
The Medical Advisory Board will be instrumental in overseeing
the protocols established for the Company's 3rd party claims
testing, and develop testing protocols for future product offerings
by the Company. While Aquaprin needs no further development and
testing as an OTC product, the Board will establish protocols for
developing a prescription strength version of the Company's future
product line. Additionally, the Board will assist in guiding
products to the medical community to help ensure doctors'
endorsement of the Aquaprin product line. This will aid in the
commercial success of the Aquaprin technology.
Dr. Hernandez has served as a hematopathologist in Orlando,
Florida since 2009. Before moving to Florida, he served in the same
capacity for Kaiser Permanente in Los Angeles, beginning in 1994.
He received his M.D. from the University of Miami School of
Medicine in 1987. Dr. Hernandez is certified by the American Board
of Pathology, and is a member of the American Society of Hematology
(ASH) and the Florida Society of Pathologists.
"I am pleased to join the Medical Advisory Board for PharmStar,"
stated Dr. Hernandez. "Providing new products for medical treatment
is important because it introduces new options for therapy and for
modifying disease course, and Aquaprin is no different. I have been
involved with PharmStar for a few years, and am honored to take a
critical role in bringing this to market. I hope that our work on
the Advisory Board will provide beneficial information about
Aquaprin's safety, advantage and utility, and at the same time meet
the needs of the Board of Directors."
Dr. Hernandez continued, "I applaud Mr. Phykitt for developing
this Advisory Board. It shows concern and respect for the retail
public in general and the medical profession in particular."
CEO Howard Phykitt stated, "I am happy that Dr. Hernandez has
decided to accept our invitation, and become a member of this
important Board. He is a caring and passionate physician, and will
be a positive influence on the path we create to bring Aquaprin to
market."
About PharmStar Pharmaceuticals, Inc.
PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based drug
development, manufacturing and marketing company and the innovator
of the FDA-approved liquid pain reliever, Aquaprin™. In development
since 1993 with over $3 million invested to-date, Aquaprin™ is a
liquid derivative of aspirin, and is now ready for
commercialization. Aquaprin™'s unique, multiple patent-pending
formulas are designed to dissolve nearly instantly in just 1.5
ounces or more of water. This enables the product to be absorbed
into the bloodstream up to 10 times faster than traditional OTC
pain relievers, and with little to no stomach upset.
PharmStar initially plans to sell Aquaprin™ directly to nursing
homes, outpatient and health care clinics, emergency units of
hospitals nationwide, as well as retail distribution in selected
local markets and third-party websites to be announced. All package
engineering, product stability, shelf life testing and quality
control research has been completed. PharmStar's headquarters are
located in Wilson, NC. www.pharmstarinc.com
Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within
the meaning of the federal securities laws, commonly identified by
such terms as "believes," "will," "looking ahead," "anticipates,"
"estimates" and other terms with similar meaning. Although the
Company believes that the assumptions upon which its
forward-looking statements are based are reasonable, it can give no
assurance that these assumptions will prove to be correct.
Important factors that could cause actual results to differ
materially from the Company's projections and expectations are
disclosed in the Company's filings with the Securities and Exchange
Commission. All forward-looking statements in this press release
are expressly qualified by such cautionary statements and by
reference to the underlying assumptions.
Contact: PharmStar Pharmaceuticals, Inc. 919-794-7000
info@pharmstarinc.com www.pharmstarinc.com Investor Contact:
investors@pharmstarinc.com